3,5-二氯-N-(3-氯苯基)-2-羟基苯甲酰胺 | 6137-38-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 3,5-二氯-N-(3-氯苯基)-2-羟基苯甲酰胺
• 英文名称: 3,5-dichloro-N-(3-chlorophenyl)-2-hydroxybenzamide
• 英文别名: 3.3'.5-Trichlor-salicylanilid
• CAS: 6137-38-8
• 化学式: C₁₃H₈Cl₃NO₂
• 分子量: 316.571
• InChiKey: JXHXHDUSHCEDGY-UHFFFAOYSA-N

物化性质

• 沸点：
  382.2±42.0 °C(Predicted)
• 密度：
  1.562±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.8
• 重原子数：
  19
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  49.3
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  3,5-二氯-N-(3-氯苯基)-2-羟基苯甲酰胺 、 氯甲酸乙酯 以 吡啶 为溶剂， 反应 1.0h， 以63%的产率得到6,8-Dichloro-3-(3-chlorophenyl)-1,3-benzoxazine-2,4-dione
  参考文献：
  名称：

  抗分枝杆菌物质的化学结构与其对非典型菌株的活性之间的关系。第 14 部分：3-Aryl-6,8-dihalo-2H-1,3-benzoxazine-2,4 (3H) -diones

  摘要：

  6,8-二氯-3-苯基-2H-苯并恶嗪-2,4(3H)-二酮的八种衍生物和6,8-二溴-3-苯基-2H-1,3-苯并恶嗪-的九种衍生物苯环上取代的 2,4 (3H)-二酮是通过相应的水杨酰苯胺与氯甲酸乙酯反应制备的。在体外评估了这些化合物对结核分枝杆菌、堪萨斯分枝杆菌和鸟分枝杆菌的抗分枝杆菌活性。它们的活性随着苯环上取代基的疏水性和吸电子能力的增加而增加。

  DOI：

  10.1002/(sici)1521-4184(199801)331:1<3::aid-ardp3>3.0.co;2-2
• 作为产物：
  描述：

  3,5-二氯水杨酸 在 氯化亚砜 作用下， 以 二氯甲烷 为溶剂， 反应 0.5h， 生成 3,5-二氯-N-(3-氯苯基)-2-羟基苯甲酰胺
  参考文献：
  名称：

  Discovery and Structure–Activity Relationships of Modified Salicylanilides as Cell Permeable Inhibitors of Poly(ADP-ribose) Glycohydrolase (PARG)

  摘要：

  The metabolism of poly(ADP-ribose) (PAR) in response to DNA strand breaks, which involves the concerted activities of poly(ADP-ribose) polymerases (PARPs) and poly(ADP-ribose) glycohydrolase (PARG), modulates cell recovery or cell death depending upon the level of DNA damage. While PARP inhibitors show high promise in clinical trials because of their low toxicity and selectivity for BRCA related cancers, evaluation of the therapeutic potential of PARG is limited by the lack of well-validated cell permeable inhibitors. In this study, target-related affinity profiling (TRAP), an alternative to high-throughput screening, was used to identify a number of druglike compounds from several chemical classes that demonstrated PARG inhibition in the low-micromolar range. A number of analogues of one of the most active chemotypes were synthesized to explore the structure activity relationship (SAR) for that series. This led to the discovery of a putative pharmacophore for PARG inhibition that contains a modified salicylanilide structure. Interestingly, these compounds also inhibit PARP-1, indicating strong homology in the active sites of PARG and PARP-1 and raising a new challenge for development of PARG specific inhibitors. The cellular activity of a lead inhibitor was demonstrated by the inhibition of both PARP and PARG activity in squamous cell carcinoma cells, although preferential inhibition of PARG relative to PARP was observed. The ability of inhibitors to modulate PAR metabolism via simultaneous effects on PARPs and PARG may represent a new approach for therapeutic development.

  DOI：

  10.1021/jm200325s

文献信息

• ORAL COMPOSITIONS FOR TREATING PLAQUE AND GINGIVITIS CONTAINING A NONCATIONIC ANTIBACTERIAL AGENT AND A BICARBONATE SALT
  申请人：THE PROCTER & GAMBLE COMPANY

  公开号：EP0693919B1

  公开（公告）日：1998-12-23
• US5290541A
  申请人：——

  公开号：US5290541A

  公开（公告）日：1994-03-01
• [EN] METHODS FOR MAKING ORAL COMPOSITIONS
  申请人：THE PROCTER & GAMBLE COMPANY

  公开号：WO1992010991A1

  公开（公告）日：1992-07-09

  (EN) Disclosed is a method for making oral compositions which are effective against plaque and gingivitis and contain a noncationic water insoluble antibacterial agent. The process comprises mixing said antibacterial agent with a solvent and adding this combination to the composition at the same time as a surfactant or just after said surfactant is added.(FR) On décrit un procédé de préparation de compositions orales agissant efficacement contre la plaque dentaire et la gingivite et contenant un agent antibactérien non-cationique et insoluble dans l'eau. Le procédé consiste à mélanger ledit agent antibactérien avec un solvant et à ajouter ce mélange à la composition en même temps qu'un agent tensioactif, ou juste après que ledit agent tensioactif ait été ajouté.